MATINAS BIOPHARMA HOLDINGS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Cash and Cash Equivalents, Period Increase (Decrease) of $3.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-16
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$1.69M.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$2.27M, a 140.16% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$4.57M.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $11.73M.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $3.20M, a 264.40% increase from fiscal 2016.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $878.45K, a 38.06% increase from fiscal 2015.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $636.28K.
- MATINAS BIOPHARMA HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$8.25M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$3.96M derived: sum of 2 quarters · filed 2018-03-16 | -$8.53M derived: sum of 3 quarters · filed 2018-03-16 | $3.20M 10-K · filed 2018-03-16 |
| 2017-09-30 | -$2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$6.83M derived: sum of 2 quarters · filed 2017-11-14 | $4.90M 10-Q · filed 2017-11-14 | $2.78M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | -$4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $7.16M 10-Q · filed 2017-08-08 | $5.05M derived: sum of 3 quarters · filed 2018-03-16 | $10.69M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $11.73M 10-Q · filed 2017-05-15 | $9.62M derived: sum of 2 quarters · filed 2018-03-16 | $15.26M derived: sum of 3 quarters · filed 2018-03-16 | $14.16M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $3.53M derived: sum of 2 quarters · filed 2018-03-16 | $2.43M derived: sum of 3 quarters · filed 2018-03-16 | $878.45K 10-K · filed 2018-03-16 |
| 2016-09-30 | $5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $4.55M derived: sum of 2 quarters · filed 2017-11-14 | $2.99M 10-Q · filed 2017-11-14 | $1.86M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$2.65M 10-Q · filed 2017-08-08 | -$3.78M derived: sum of 3 quarters · filed 2018-03-16 | -$6.03M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | -$1.55M 10-Q · filed 2017-05-15 | -$2.69M derived: sum of 2 quarters · filed 2018-03-16 | -$4.93M derived: sum of 3 quarters · filed 2018-03-16 | -$2.94M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$3.38M derived: sum of 2 quarters · filed 2018-03-16 | -$1.39M derived: sum of 3 quarters · filed 2018-03-16 | $636.28K 10-K · filed 2018-03-16 |
| 2015-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$253.77K derived: sum of 2 quarters · filed 2016-11-14 | $1.77M 10-Q · filed 2016-11-14 | -$644.01K derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $4.01M 10-Q · filed 2016-08-15 | $1.60M derived: sum of 3 quarters · filed 2016-08-15 | -$41.98K derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | $2.03M 10-Q · filed 2016-05-13 | -$390.24K derived: sum of 2 quarters · filed 2016-05-13 | -$2.03M derived: sum of 3 quarters · filed 2016-05-13 | -$3.94M derived: sum of 4 quarters · filed 2016-05-13 |
| 2014-12-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$4.06M derived: sum of 2 quarters · filed 2016-03-30 | -$5.97M derived: sum of 3 quarters · filed 2016-03-30 | -$8.25M 10-K · filed 2016-03-30 |
| 2014-09-30 | -$1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$3.55M derived: sum of 2 quarters · filed 2015-11-10 | -$5.83M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | -$1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$4.19M 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | -$2.28M 10-Q · filed 2015-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |